TABLE 4.

Multivariate Analysis of Predictors of Mortality in LT Recipients With COVID‐19

	Univariate			Multivariate
	P Value	OR	95% CI	P Value	Hazard Ratio	95% CI
Liver injury	0.002	4.96	1.80‐13.65	0.007	6.91	1.67‐28.48
Age (>65 years)	0.150	2.15	0.82‐5.63	0.130	2.93	0.73‐11.81
Sex (female)	0.229	0.5	0.19‐1.30	0.066	3.69	1.11‐12.21
Race, non‐Hispanic White	0.803	0.78	0.28‐2.13	0.224	1.17	0.35‐3.86
Ethnicity, Hispanic	1.000	1	0.36‐2.50	0.153	2.01	0.67‐13.38
DM	0.004	4.630	1.65‐12.96	0.044	3.7	1.04‐13.09
HTN	0.028	3.41	1.18‐9.78	0.763	2.04	0.61‐6.94
Active cancer	0.027	6.75	1.21‐37.63	0.127	10.86	1.04‐113.47
Hyperlipidemia	0.404	1.72	0.60‐4.92
Obesity	1.000	0.86	0.29‐2.57
Metabolic syndrome	0.140	2.45	0.82‐7.44
Time transplant (<1 year)	1.000	0.91	0.35‐2.40
Immunosuppression Modified	0.084	2.51	0.90‐6.95
Tacrolimus	0.424	3.45	0.39‐29.47
Cyclosporine	0.332	0.75	0.67‐0.84
MMF	0.337	1.73	0.66‐4.51
Prednisone, low dose	0.592	1.41	0.50‐3.96

Bold signifies statistically significant.

Abbreviations: HLD, hyperlipidemia; MMF, mycophenolate.